Stay updated with breaking news from Director Robert Eckert. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Amgen (NASDAQ:AMGN – Get Rating) was downgraded by equities researchers at Barclays from an “equal weight” rating to an “underweight” rating in a research report issued on Monday, MarketBeat Ratings reports. They currently have a $234.00 target price on the medical research company’s stock. Barclays‘s price target indicates a potential downside of 13.99% from the […]
Sawgrass Asset Management LLC purchased a new stake in shares of Amgen Inc. (NASDAQ:AMGN – Get Rating) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 77,946 shares of the medical research company’s stock, valued at approximately $18,849,000. Amgen comprises approximately 2.0% of […]